ClinicalTrials.gg
CompletedNCT02071784MACOUPLING-CADUpdated Mar 5, 2026

Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)

An observational study in CADASIL, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
60
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The aim of this study is to investigate using fMRI methods, EEG and dedicated mathematical models, the potential alterations of neurovascular coupling in CADASIL.

Read the detailed description

Comparison study of parameters derived from mathematical models of neurovascular coupling and obtained using fMRI (Bold signal, ASL and EEG).

02

Conditions studied

  • CADASIL

Browse trials for

03

In context

CADASIL

33 studies on the registry are indexed under CADASIL; 18 are open to participants now.

This study's enrollment of 60 is below the median of 168 across 22 observational studies indexed under CADASIL.

Browse CADASIL studies →

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

CADASIL patients compared to age-matched controls (two groups)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CADASIL group: typical NOTCH3 mutation, age less than 60 years, rankin score at 0-1, active social insurance

Exclusion criteria

Exclusion Criteria:

  • MRI and use of any treatment known to interfere with neurovascular coupling, pregnancy, lack of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
60 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. model-derived parameters of neurovascular coupling

    Time frame: one time point

07

Study locations

1 site
  • CENIR, Hopital Pitié Salpetriere
    Paris, Paris 75013, France
08

References and documents

Publications

  • Huneau C, Houot M, Joutel A, Beranger B, Giroux C, Benali H, Chabriat H. Altered dynamics of neurovascular coupling in CADASIL. Ann Clin Transl Neurol. 2018 May 21;5(7):788-802. doi: 10.1002/acn3.574. eCollection 2018 Jul. PubMed 30009197 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02071784
Responsible party
Sponsor
First posted
Feb 26, 2014
Start date
Jul 8, 2014
Primary completion
Oct 24, 2016
Completion
Oct 24, 2016
Last update
Mar 5, 2026

Study contacts

Hugues Chabriat, MD PhD
principal investigator · INSERM and APHP

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion